

## A BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy

<b>Drug Name</b>	***0007
<b>Description</b>	***0007 is a BCMA/CD19 dual-target CAR-T cell immunotherapy in early clinical development for the treatment of relapsed or refractory multiple myeloma.
<b>Target</b>	BCMA; CD19
<b>Drug Modality</b>	CAR T cells
<b>Indication</b>	Multiple Myeloma
<b>Product Category</b>	Cancer Immunotherapy
<b>Mechanism of Action</b>	Targeting B-Lymphocyte Antigen CD19 and B-cell Maturation Protein (BCMA)
<b>Status</b>	Phase I
<b>Patent</b>	Granted

### More Detail Available Upon Request

We look forward to hearing from you.